康码 D2Pi AutoLab 无细胞智造系统，打破 AI 生产力创新鸿沟。
Kangma D2Pi AutoLab’s cell-free intelligent manufacturing system bridges the gap between AI-driven productivity and real-world biological innovation.
当前 AI + 生物医药生产过程中，AI 高通量筛选技术在生物大分子领域已展现出惊人的效率，将早期发现周期从数年压缩至数月。
然而，从“计算器里的成功”到“工厂里的良药”，二者之间横亘着一条充满挑战的产业化鸿沟。
过剩产能导致的模型趋同演化，AI的超高算力可以短时间生成数以百计甚至千记的数据，这些数据在训练过程中逐渐趋同，但缺乏湿实验验证的数据，最终难以抢占市场。
因此湿实验效率大大限制了生产力的加速，更阻止了自身竞争力。
康码 D2Pi Autolab 无细胞智造系统，结合了康码研发的 D2P 技术，仅需三小时即可实验 300 个蛋白的合成，从微升到吨级的自由放大，让工艺开发大大加速，为生物医药产业化“按下加速键”，提升市场竞争力。
In today’s AI + biopharmaceutical R&D landscape, AI-powered high-throughput screening has demonstrated remarkable efficiency in the discovery of biological macromolecules, shortening early-stage discovery timelines from years to months.
However, a significant commercialization gap remains between“success in computation” and “effective medicines in the real world.”
The proliferation of computational capacity can drive model convergence and diminishing differentiation. AI can generate hundreds or even thousands of candidate molecules in a short period of time, but without sufficientwet-lab validation, these computational results are difficult to translate into differentiated products and ultimately into market success.
As a result,wet-lab throughput and experimental efficiency have become major bottlenecks limiting the acceleration of AI-driven biological innovation, while also constraining the ability of companies to build and maintain competitive advantages.
Kangma D2Pi AutoLab’s cell-free intelligent manufacturing system combines Kangma’s proprietaryD2P technology to enable the synthesis of up to 300 proteins in just three hours. With flexible scalability from microliter-scale experiments to ton-scale manufacturing, the platform dramatically accelerates process development and puts the biopharmaceutical industry on the fast track to commercialization—helping companies accelerate innovation and strengthen their market competitiveness.
